AI Terminal
Recordati Industria Chimica e Farmaceutica
Report Publication Announcement • Jan 28, 2025
4056_rns_2025-01-28_b78a517f-67cf-4cb1-bfb5-7cdd6914e731.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
RECORDATI: 2025 CORPORATE EVENTS' CALENDAR
Milan, 28th January 2025 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2025:
| 13th February | Board of Directors' meeting to approve the 2024 preliminary consolidated results. At 4.00 pm (CET): conference call on the 2024 preliminary consolidated results. |
|---|---|
| 18th March | Board of Directors' meeting to approve the 2024 consolidated financial statements and the draft of Recordati S.p.A.'s 2024 financial statements. |
| 29th April | Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2024 financial statements and to appoint Board of Directors. |
| th May 8 |
Board of Directors' meeting to approve the 2025 first quarter results, as additional voluntary financial reporting. |
| 29th July | Board of Directors' meeting to approve the 2025 half-yearly report. |
| 11th November | Board of Directors' meeting to approve the 2025 first nine months' results, as additional voluntary financial reporting. |
Recordati S.p.A. announces that the payment of the balance of the 2024 financial year dividend is planned for 21 stMay 2025, on each outstanding share at 19th May 2025 (ex-dividend rate) and record date 20 th May 2025, while the payment of the interim dividend for the 2025 financial year is planned for 26 th November 2025, on each outstanding share at 24th November 2025 (ex-dividend rate) and record date at 25th November 2025.
Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.
Any amendments to the above calendar as well as any dedicated meetings/conference calls with the financial community will be promptly notified to the market and will be made available in the company website.
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Tel. +39 02 487871 Fax +39 02 40073747 www.recordati.com
Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832
Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l
EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.
Investor Relations
Eugenia Litz +44 7824 394 750 [email protected] Gianluca Saletta +39 348 979 4876 [email protected]
Media Relations
ICR Healthcare US: Alexis Feinberg +1 203 939 2225 [email protected] UK, Europe & Rest of World: Jessica Hodgson +44 7561 424 788 [email protected]
This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast for a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the activities of the Recordati Group, and, as such, it is not intended as a medical scientific indication or recommendation, or as advertising.